The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

The pharma giant announced Tuesday morning that the monthly MariTide treatment helped patients with obesity lose, on average, ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...